The role of adenosinergic pathway in human autoimmune diseases.
Autoimmune diseases are characterized by the abnormal immune response against self-tissue, which are caused by the failure of nature immune homeostasis. Nature immune homeostasis represents the normal state of appropriate immune response to nonself-antigen and unresponsiveness to self-antigens. In normal situation, immune homeostasis is regulated by immunosuppressive signal and immunostimulating signal together. Accumulating data have demonstrated that the adenosinergic pathway played key roles in immune suppression and shield body from an excessive inflammatory response. The deficiency of adenosinergic pathway results in the imbalance between the pro- and anti-inflammatory activities. Thus, researchers pay much attention to the role of adenosinergic pathway in autoimmune diseases development. To date, accumulating data have suggested an important role of adenosinergic pathway-related molecules (i.e., CD39, CD73, ADA, adenosine receptors, etc.) in many types of human autoimmune diseases. More importantly, these findings have presented potential value of adenosinergic pathway analysis to be used for autoimmune diseases diagnosis, monitoring and treatment. In this review, we will provide a comprehensive description of the role of adenosinergic pathway in human autoimmune diseases.
Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. tdjyk3@fmmu.edu.cn.
Ke
K
Dong
Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Zhao-Wei
ZW
Gao
Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Hui-Zhong
HZ
Zhang
D015720:5'-Nucleotidase / Q000378:metabolism; D000241:Adenosine / Q000378:metabolism*; D000243:Adenosine Deaminase / Q000378:metabolism; D015703:Antigens, CD / Q000378:metabolism; D001081:Apyrase / Q000378:metabolism; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance; D007159:Immunologic Tests; D007165:Immunosuppression Therapy; D058990:Molecular Targeted Therapy; D018047:Receptors, Purinergic P1 / Q000378:metabolism; D015398:Signal Transduction
D015703:Antigens, CD; D018047:Receptors, Purinergic P1; D015720:5'-Nucleotidase; C548482:ADA protein, human; D000243:Adenosine Deaminase; D001081:Apyrase; C067869:CD39 antigen; D000241:Adenosine
Adenosine receptor; Adenosinergic pathway; Autoimmune diseases; Immunosuppression
Zhonghua Yi Xue Za Zhi. 2009 Jun 16;89(23):1636-8
19957514
Arthritis Rheum. 2009 May;60(5):1472-83
19404966
Cell Immunol. 2014 Aug;290(2):217-25
25086239
Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2509-14
25675517
Curr Rheumatol Rep. 2009 Oct;11(5):365-70
19772832
Ann Neurol. 2001 May;49(5):650-8
11357956
J Immunol. 2013 Jan 1;190(1):138-46
23225885
Zhonghua Nei Ke Za Zhi. 2010 Sep;49(9):772-5
21092450
Front Immunol. 2012 Jul 05;3:190
22783261
J Immunol. 2013 Sep 15;191(6):2926-37
23956420
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9325-30
18591671
Clin Rheumatol. 2016 Sep;35(9):2359-62
26886128
PLoS One. 2016 Feb 26;11(2):e0150078
26919582
J Immunol. 2007 Feb 15;178(4):2579-88
17277168
Pharmacol Res Perspect. 2015 Nov 16;3(6):e00189
27022463
Eur J Immunol. 2015 Feb;45(2):344-55
25378177
Surv Ophthalmol. 2016 Sep-Oct;61(5):680-8
27131478
Diabetes. 2013 Dec;62(12):4208-19
24264405
Clin Immunol. 2011 Nov;141(2):197-204
21920821
J Immunol. 2015 Mar 15;194(6):2487-92
25681339
Clin Immunol. 2014 Sep;154(1):1-12
24858580
Trends Mol Med. 2013 Jun;19(6):355-67
23601906
J Clin Diagn Res. 2015 Sep;9(9):BC08-10
26500897
J Rheumatol. 2008 Jan;35(1):41-8
18050382
Cell Mol Immunol. 2015 Oct 05;:null
26435067
FASEB J. 2007 Aug;21(10):2379-88
17405852
J Autoimmun. 2016 Aug;72:102-12
27210814
J Neurol Sci. 1990 Dec;100(1-2):174-7
2089134
Curr Mol Med. 2012 Dec;12(10):1261-72
22709273
Cytokine. 2015 Jul;74(1):101-7
25466295
Gen Comp Endocrinol. 2013 Jun 15;187:86-94
23453966
Exp Cell Res. 2014 Feb 1;321(1):3-10
24315942
Lupus. 2011 Jun;20(7):667-77
21183557
Nat Rev Endocrinol. 2015 Apr;11(4):228-41
25687993
Hepatology. 2014 Mar;59(3):1007-15
23787765
Intern Med. 1995 Feb;34(2):81-4
7727883
Rheumatology (Oxford). 2011 Aug;50(8):1366-72
21489974
Clin Dev Immunol. 2012;2012:823085
22761634
Mol Immunol. 2015 Feb;63(2):559-65
25458315
Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):865-9
22423038
Nat Rev Drug Discov. 2008 Sep;7(9):759-70
18758473
J Neurosci. 2004 Feb 11;24(6):1521-9
14960625
Arthritis Res Ther. 2013 Aug 23;15(4):R97
23968496
Immunol Rev. 2001 Dec;184:117-28
11918681
Semin Hematol. 2016 Apr;53 Suppl 1:S23-6
27312159
Rheumatol Int. 2012 Jun;32(6):1633-8
21350874
Int J Mol Med. 2011 Nov;28(5):727-31
21887476
Am J Physiol Cell Physiol. 2011 Aug;301(2):C530-9
21593451
Arthritis Rheumatol. 2015 Feb;67(2):545-54
25418634
Eur J Immunol. 2013 Sep;43(9):2430-40
23749427
Mediators Inflamm. 2015;2015:460610
25691808
Pharmacol Ther. 2008 Dec;120(3):233-53
18848843
Nan Fang Yi Ke Da Xue Xue Bao. 2012 Jun;32(6):886-9
22699077
Mol Med. 2008 Mar-Apr;14 (3-4):116-23
18163162
Eur J Immunol. 2012 May;42(5):1140-51
22539289
PLoS One. 2015 Jul 06;10(7):e0132348
26147733
Trends Immunol. 2004 Jan;25(1):33-9
14698282